Pharmaceuticals
BioKangtai's adenovirus vector COVID-19 vaccine obtained EUA in Indonesia
SHENZHEN, China, Nov. 3, 2021 /PRNewswire/ -- As reported by Indonesian National Agency of Drug and Food Control (BPOM), BPOM grants the Emergency Use Authorization (EUA) for COVID-19 Vaccine (ChAdOx1-S[recombinant])/KconecaVac manufactured by Shenzhen Kangtai Biological Products Co., Ltd. It is ...
2021-11-03 19:02
1603
Tabernacle Health Group Launches Revolutionary Immunity Booster!
SINGAPORE, Nov. 3, 2021 /PRNewswire/ -- As a result of the pandemic, boosting one's immune system has never been more crucial. Consisting of numerous chemicals, cells, proteins, and tissues that work together, the immune system is responsible for creating, storing, and distributing white blood ce...
2021-11-03 10:00
2177
Kintor Pharma Doses First Patient in Clinical Trial of ALK-1 in Combination with KN046 In Advanced or Refractory Solid Tumors
SUZHOU, China, Nov. 3, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has enrolled and dosed its first patient with advanced...
2021-11-03 08:32
1973
Daewoong's "Leaps and Bounds" Q3 Performance, Exceeds KRW 20B in Operating Income for Three Consecutive Quarters
* Advancement of Nabota and prescriptions... KRW 290.6B sales and KRW 22.7B operating income * Expanding growth momentum with the release of Fexuprazan in Korea and Nabota inEurope next year SEOUL, South Korea, Nov. 2, 2021 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) (CEOSengho Jeon) a...
2021-11-02 21:00
1538
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer
HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that AK112 (PD-1/VEGF bi-specific antibody), the novel immuno-oncology drug independently developed by the Company, obtained approval from the Center for Drug Evaluation (CDE) of the National Medical Products Ad...
2021-11-02 11:53
1719
Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma
SHANGHAI and HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-11-02 08:30
3221
111 to Announce Third Quarter 2021 Unaudited Financial Results on November 19, 2021 - Conference Call to Follow
SHANGHAI, Oct. 28, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...
2021-11-02 04:57
2382
Qilian International Holding Group Limited Donates Pharmaceutical Products Gan Di Xin® Worth RMB500,000 and Other Materials to Help Fight Local COVID-19 Epidemic
JIUQUAN, China, Nov. 1, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that recently, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), the Comp...
2021-11-01 20:00
1361
I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments
SHANGHAI and GAITHERSBURG, Md., Nov. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced the appointment ofJohn Long as the Company's Chief Finan...
2021-11-01 20:00
1507
Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study
* U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study * The PREVAIL Study remains on target to initiate by end of 2021 and is expected to read out topline data by end of 2022 ADELAIDE, A...
2021-11-01 18:00
2219
Farrer Park Hospital Introduced Actinium-225 PSMA Nuclear Therapy for Advanced Prostate Cancer
Earlier trials using Actinium-225 PSMA showed an improved biochemical response and better cancer-killing effects as Actinium-225 PSMA uses a much more potent radioactive ligand. SINGAPORE, Nov. 1, 2021 /PRNewswire/ -- Prostate cancer is the 3rd most common cancer among Singaporean men. Every day...
2021-11-01 08:15
1968
Everest Medicines Announces Share Repurchase Transaction Details
SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that it ...
2021-11-01 08:00
2189
Operating Income of Yiling Pharmaceutical in First 3 Quarters Reaches CNY 8.112 Billion, Up 25.81%
SHIJIAZHUANG, China, Oct. 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical released the three-quarter report on the evening ofOctober 28. In the first three quarters, the operating income of the company reachedCNY 8.112 billion, up 25.81% year on year; the net profit attributable to shareholders of...
2021-10-29 17:17
1373
3M Health Care and Thermo Fisher Scientific Collaborate to Increase Process Efficiency and Scalability in Commercial Therapeutic Manufacturing
- Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers - Solution enables manufacturers to optimize manufacturing capacity, quality, efficiency and scalability ST. PAUL, Minn., Oct. 29, 2021 /PRNewswire/ -- 3M Separation and Purification ...
2021-10-29 15:45
1804
IMPACT Therapeutics Announced ATR Inhibitor IMP9064 IND Clearance by FDA
SHANGHAI, Oct. 29, 2021 /PRNewswire/ -- IMPACT Therapeutics announced that its ATR inhibitor IMP9064 has received the IND clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, which will begin soon in the U.S. This will be the first in human study for the A...
2021-10-29 14:12
1465
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC
SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 inChina (ENREACH-LUNG-02) recently completed the first drug administration. ENREACH-LUNG-02 is a multi-center, open-label, randomized...
2021-10-29 09:36
2356
Hanmi Science Consortium Drives Ambitious Project for Worldwide Vaccine Equity
SEOUL, South Korea, Oct. 29, 2021 /PRNewswire/ -- Hanmi Science doesn't just want the world to know they are committed to vaccine equity, they want to prove it. Mr. Lim, CEO of Hanmi Science, echoes the concerns of Mr.Bill Gates, co-founder of the Bill & Melinda Gates Foundation. As Mr. Gates sta...
2021-10-29 09:27
2239
ImmunoForge Inc. receives U.S. FDA ODD for PF1801
SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire/ -- ImmunoForge (Co-CEOsSung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 which is in development for treatment of D...
2021-10-29 05:50
2184
Jubilee Biotech has developed JUBIwatch, "Health and Life are now wearable"
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- Jubilee Biotech, a startup in South Korea, has developed JUBIwatch, a smart watch and medication management platform that uses microneedles to administer exact amounts of medication at set times. "Wearing, setting up, and sending information on m...
2021-10-28 21:00
1112
HanAll Biopharma Reports Third Quarter 2021 Results
* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 * Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively SEOUL, South Korea, Oct...
2021-10-28 21:00
1437
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 273 media titles]
2024-11-29 20:33
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
13411
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
9486
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8327
